Functionally, the reduced skin lesions in IFNAR-deficient SLE model mice (Nickerson et al., 2013) is consistent with this idea, and, indeed, anifrolmab is especially efficacious for skin disease in SLE patients (Furie et al., 2017; Merrill et al., 2018; Morand et al., 2020). The gene discussed is IFNAR1; the disease is systemic lupus erythematosus.